JPH04257522A - Dialyzing agent for sodium bicarbonate - Google Patents

Dialyzing agent for sodium bicarbonate

Info

Publication number
JPH04257522A
JPH04257522A JP3036525A JP3652591A JPH04257522A JP H04257522 A JPH04257522 A JP H04257522A JP 3036525 A JP3036525 A JP 3036525A JP 3652591 A JP3652591 A JP 3652591A JP H04257522 A JPH04257522 A JP H04257522A
Authority
JP
Japan
Prior art keywords
agent
sodium bicarbonate
acid
solution
dialysis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP3036525A
Other languages
Japanese (ja)
Inventor
Nobuo Ito
信夫 伊藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nikkiso Co Ltd
Towa Pharmaceutical Co Ltd
Original Assignee
Nikkiso Co Ltd
Towa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nikkiso Co Ltd, Towa Pharmaceutical Co Ltd filed Critical Nikkiso Co Ltd
Priority to JP3036525A priority Critical patent/JPH04257522A/en
Publication of JPH04257522A publication Critical patent/JPH04257522A/en
Pending legal-status Critical Current

Links

Abstract

PURPOSE:To provide the title powdered agent advantageous for reservation or transportation, without the need for any additional pH adjusting ingredient, capable of giving a dialyzing solution of desired pH value by simply dissolution in water without causing any precipitation. CONSTITUTION:The objective dialyzing agent comprising electrolyte components, made up of a group A consisting of at least one ingredient (in the form of granulated particles containing an acid as pH adjusting agent) other than sodium bicarbonate and a group B consisting mainly of sodium bicarbonate.

Description

【発明の詳細な説明】[Detailed description of the invention]

【0001】0001

【産業上の利用分野】本発明は、重曹透析用剤に係るも
のである。
[Industrial Field of Application] The present invention relates to a sodium bicarbonate dialysis agent.

【0002】0002

【従来の技術】透析用剤は、透析液を作製するための薬
剤である。透析液は、人工腎臓、血液透析、腹膜透析な
どにより本来腎臓が行う機能に代わり、体液の老廃物を
取り去り、更には血液中に必要な成分を補うために用い
るものであり、アルカリ化剤として重曹を用いる重曹透
析用剤が生理的に好ましいものであるため需要が増加し
てきている。
BACKGROUND OF THE INVENTION A dialysis agent is a drug used to prepare a dialysate. Dialysis fluid is used in artificial kidneys, hemodialysis, peritoneal dialysis, etc. to replace the functions normally performed by the kidneys, remove waste products from body fluids, and supplement necessary components in the blood, and is used as an alkalizing agent. Demand for sodium bicarbonate dialysis agents using sodium bicarbonate is increasing because they are physiologically preferred.

【0003】重曹透析液としては、以下に示すような電
解質イオン組成を有するものが用いられ、使用時のpH
は7.2 〜7.4 に調整されている。 Na+               120 〜15
0  mEq/lK  +             
  0.5 〜3.0 mEq/lCa++     
         1.5 〜4.5  mEq/lM
g++                0 〜2.0
 mEq/lCl−                
90 〜135  mEq/lCH3 COO−   
      5 〜 35 mEq/lHCO3−  
           20 〜 35 mEq/lブ
ドウ糖              0 〜250  
g/l
[0003] As a sodium bicarbonate dialysate, one having an electrolyte ion composition as shown below is used, and the pH at the time of use is
is adjusted to 7.2 to 7.4. Na+ 120 ~ 15
0 mEq/lK +
0.5 to 3.0 mEq/lCa++
1.5 to 4.5 mEq/lM
g++ 0 ~ 2.0
mEq/lCl-
90 to 135 mEq/lCH3COO-
5 to 35 mEq/lHCO3-
20-35 mEq/l glucose 0-250
g/l

【0004】普通、重曹透析液は、溶解度の関係
から重曹以外の必要電解質およびブドウ糖成分(以下A
剤という。)の約2.5kg に水を加えて約10リッ
トルの容積の原液とし、透析時に、この原液とアルカリ
剤としての重曹水溶液とを混合して、全量を350 リ
ットルに希釈して用いられる。重曹については粉末状に
て保存あるいは輸送して使用の直前に溶解することもあ
る。
Normally, baking soda dialysate contains necessary electrolytes and glucose components (hereinafter referred to as A) other than baking soda due to solubility.
It is called a drug. ) is added to about 2.5 kg of water to make a stock solution with a volume of about 10 liters, and during dialysis, this stock solution is mixed with an aqueous sodium bicarbonate solution as an alkaline agent to dilute the total volume to 350 liters. Baking soda may be stored or transported in powder form and dissolved immediately before use.

【0005】前記のように、A剤の溶液と重曹水溶液と
を予め調製しておく場合には、これを濃厚な原液とした
としても、かなりの容積と重量になり、貯留や運搬や使
用時の取扱に不便をきたす欠点がある。この欠点を避け
るため、A剤を粉体として貯留や運搬を行う場合には、
A剤の溶解して重曹と混合する際に、なかに含まれるカ
ルシウム成分またはマグネシウム成分が沈澱を生成しや
すいという問題点がある。このような問題点を避けるた
め、あるいは透析液のpHを生理的に好ましいものに調
整するために、普通、酢酸あるいは塩酸等の酸が添加さ
れる。
[0005] As mentioned above, when the solution of Part A and the aqueous sodium bicarbonate solution are prepared in advance, even if they are made into a concentrated stock solution, they take up a considerable volume and weight, making it difficult to store, transport, and use them. There is a drawback that it is inconvenient to handle. To avoid this drawback, when storing or transporting agent A as a powder,
There is a problem in that when agent A is dissolved and mixed with baking soda, the calcium component or magnesium component contained therein tends to form a precipitate. In order to avoid such problems or to adjust the pH of the dialysate to a physiologically favorable value, an acid such as acetic acid or hydrochloric acid is usually added.

【0006】[0006]

【発明が解決しようとする課題】A剤が水溶液の場合は
、pH調整成分を水溶液に添加しておけば良いが、A剤
が粉末の場合は、通常pH調整成分を別薬剤とし、A剤
を溶解する純水に事前にこのpH調整成分を混合する必
要がある。このためpH調整成分の取り扱い、輸送及び
保管において安全及び品質管理上余分の注意を要するこ
ととなり、A剤を固形化した長所を減じてしまう。
[Problems to be Solved by the Invention] When Agent A is an aqueous solution, it is sufficient to add a pH adjusting component to the aqueous solution, but when Agent A is a powder, the pH adjusting component is usually added as a separate agent. It is necessary to mix this pH adjusting component in advance with the pure water in which it will be dissolved. For this reason, extra care is required in terms of safety and quality control when handling, transporting, and storing the pH-adjusting component, which reduces the advantage of solidifying Part A.

【0007】本発明の目的は、貯留および輸送に有利な
固体の透析用剤であって、pH調整成分が別途必要なく
、かつ、偏析あるいは固結の心配のない重曹透析用剤を
提供することである。
An object of the present invention is to provide a solid dialysis agent that is convenient for storage and transportation, does not require a separate pH adjusting component, and is free from segregation or caking. It is.

【0008】[0008]

【課題を解決するための手段】本発明は、重曹透析用剤
に含まれる電解質成分のうち重曹以外の成分から選ばれ
た1種以上からなる群(A剤)と、重曹を主成分とする
群(B剤)とに分け、使用時にA剤とB剤を混合して用
いる重曹透析用剤において、A剤が造粒された粒子であ
り、かつ、粒子内にpH調制剤として酸を含むことを特
徴とする重曹透析用剤を提供するものである。
[Means for Solving the Problems] The present invention provides a group (agent A) consisting of one or more electrolyte components other than sodium bicarbonate among the electrolyte components contained in a sodium bicarbonate dialysis agent, and a compound containing sodium bicarbonate as a main component. A sodium bicarbonate dialysis agent that is divided into a group (Agent B) and used by mixing Agents A and B at the time of use, where Agent A is granulated particles and contains an acid as a pH regulator within the particles. The present invention provides a sodium bicarbonate dialysis agent characterized by the following.

【0009】本発明においては、A剤が造粒された粒子
であるため、流動性が良好で発塵が少なく、取り扱いが
容易である。そして、粒子内にpH調整剤として酸を含
むので、溶解時に所定のpH7.2 〜7.4 になり
、かつカルシウムまたはマグネシウム成分の沈澱が生成
しないA剤を得ることができる。また、pH調整剤が造
粒された粒子内に含まれているため、偏析や固結の起こ
ることがない。
In the present invention, since agent A is a granulated particle, it has good fluidity, generates little dust, and is easy to handle. Since the particles contain an acid as a pH adjuster, it is possible to obtain agent A which has a predetermined pH of 7.2 to 7.4 upon dissolution and does not generate precipitates of calcium or magnesium components. Furthermore, since the pH adjuster is contained within the granulated particles, segregation and caking do not occur.

【0010】pH調整剤としては酢酸、塩酸、乳酸など
種々の酸が使用できるが、取り扱い時の安全性の点で酢
酸または乳酸が好ましく、特に酢酸が好ましい。酸の使
用量は、透析液のpHが、7.0 〜8.0 の範囲に
なるよう加えるのが好ましい。透析液のpHのより好ま
しい範囲は、7.2 〜7.4 である。酢酸あるいは
乳酸のpH調整成分は、人工透析に使用時に透析液に約
2mEq/lの濃度となる量をA剤に添加すればよい。 この範囲になるよう、pH調整剤として酢酸を使用する
場合は、酢酸をA剤全体の1.0 〜2.0 重量%添
加するのが好ましい。乳酸の場合は、A剤全体の1.5
 〜3.0 重量%添加するのが好ましい。酸は、単一
のものに限る必要はなく、複数の種類の酸を混合して用
いることもできる。
[0010] Various acids such as acetic acid, hydrochloric acid, and lactic acid can be used as the pH adjuster, but acetic acid or lactic acid is preferable from the viewpoint of safety during handling, and acetic acid is particularly preferable. The amount of acid used is preferably such that the pH of the dialysate falls within the range of 7.0 to 8.0. A more preferable range of pH of the dialysate is 7.2 to 7.4. The pH adjusting component of acetic acid or lactic acid may be added to agent A in an amount to give a concentration of about 2 mEq/l to the dialysate when used for artificial dialysis. When using acetic acid as a pH adjuster, it is preferable to add acetic acid in an amount of 1.0 to 2.0% by weight based on the total amount of A agent so as to maintain the pH within this range. In the case of lactic acid, 1.5 of the total amount of A agent
It is preferable to add up to 3.0% by weight. The acid need not be limited to a single type, and a mixture of multiple types of acids can be used.

【0011】本発明のA剤において、造粒物の細孔容積
は0.03〜0.2cc/g であることが好ましい。 細孔容積が0.03cc/gに満たない場合は、溶解速
度が遅くなる恐れがあるので好ましくない。細孔容積が
0.2cc/g を越える場合は、造粒物の強度が低下
して発塵性が現れる可能性があるので好ましくない。細
孔容積が、0.04〜0.1 cc/gである場合は、
造粒の効果が最も有効に発現するので好ましい。
In the A agent of the present invention, the pore volume of the granules is preferably 0.03 to 0.2 cc/g. If the pore volume is less than 0.03 cc/g, the dissolution rate may become slow, which is not preferable. If the pore volume exceeds 0.2 cc/g, it is not preferable because the strength of the granulated product may decrease and dust generation may occur. When the pore volume is 0.04 to 0.1 cc/g,
This is preferable because the effect of granulation is most effectively expressed.

【0012】本発明のA剤を造粒方法は、特に限定され
ないが、次の方法を使用する場合は、上記の好ましい細
孔容積を有する造粒物が得やすいので好ましい。まず、
A剤成分粉末を粒度調製し、水分が1 〜25重量%と
なるように水を加えて充分混合し、押し出し造粒機等に
より造粒後、乾燥することにより、造粒物を得る。造粒
に際し水分が1重量%に満たない場合には、粒子強度が
低くなるため粉化しやすくなり、逆に25重量%を越え
る場合には造粒が困難となる恐れがあるので、いずれも
好ましくない。
The method for granulating agent A of the present invention is not particularly limited, but it is preferable to use the following method because it is easy to obtain a granulated product having the above-mentioned preferred pore volume. first,
The particle size of the component powder of Part A is adjusted, water is added so that the moisture content becomes 1 to 25% by weight, and the mixture is thoroughly mixed. After granulation using an extrusion granulator or the like, the powder is dried to obtain a granulated product. If the moisture content is less than 1% by weight during granulation, the particle strength will be low and it will be easier to powder, while if it exceeds 25% by weight, granulation may become difficult, so both are preferred. do not have.

【0013】造粒前のA剤成分の粉末の粒子径としては
、250 μm以下、好ましくは180 μm以下、更
に好ましくは100 μm以下を採用するのが適当であ
る。粒子径が250 μmを超える場合には、最終商品
となる造粒物の機械的強度が不充分となり、粉化しやす
くなり、また溶解速度が遅くなるので好ましくない。
[0013] The particle size of the powder of the component A before granulation is suitably 250 μm or less, preferably 180 μm or less, and more preferably 100 μm or less. If the particle size exceeds 250 μm, the mechanical strength of the granulated product as a final product will be insufficient, it will be easily powdered, and the dissolution rate will be slow, which is not preferable.

【0014】造粒されたA剤粒子の粒径は、0.1 〜
10mm程度にするのが好ましい。粒径が前記範囲に満
たない場合には、流動性が阻害されたり、粉化して飛散
したりして取り扱いが困難となり、逆に前記を超える場
合には、粒子の機械的強度が低下したり、溶解に長時間
要するおそれあるので、いずれも好ましくない。A剤粒
子の粒径が、0.5 〜10mmである場合はさらに好
ましい。
[0014] The particle size of the granulated agent A particles is from 0.1 to
It is preferable to set it to about 10 mm. If the particle size is less than the above range, the fluidity may be inhibited or the particle may become powdered and scatter, making it difficult to handle.On the other hand, if the particle size exceeds the above range, the mechanical strength of the particle may decrease. Both are unfavorable since they may take a long time to dissolve. It is more preferable that the particle size of the agent A particles is 0.5 to 10 mm.

【0015】A剤中にブドウ糖を含む場合には高い温度
に加熱するとブドウ糖が黄色に着色しやすいので、この
着色の進行を防止するためにより低い温度条件で短時間
にて乾燥することが望ましい。上記造粒工程における乾
燥の際には、脱湿した後加熱された空気を用いるのが好
ましい。乾燥は30〜90℃において行うのが適当であ
る。 具体的乾燥手段としては、例えば、バンド乾燥機、円板
乾燥機、通気乾燥機、回転乾燥機等を採用することによ
り、高強度及び易溶性で均一で組成安定の良好な顆粒を
得ることが可能となる。
[0015] When part A contains glucose, the glucose tends to turn yellow when heated to a high temperature. Therefore, in order to prevent the progress of this coloring, it is desirable to dry at a lower temperature for a short time. During drying in the granulation step, it is preferable to use air that has been dehumidified and then heated. Drying is suitably carried out at 30 to 90°C. As specific drying means, for example, by adopting a band dryer, disk dryer, ventilation dryer, rotary dryer, etc., it is possible to obtain granules with high strength, easy solubility, uniformity, and good compositional stability. It becomes possible.

【0016】本発明におけるpH調整成分は、A剤成分
を造粒し乾燥した後に、添加するのが好ましい。pH調
整成分は、造粒されたA剤粒子内に均一に添加されてい
ることが好ましく、pH調整成分をA剤に均一に添加す
る具体的手段としては、例えばA剤を撹拌しつつpH調
整成分をスプレーにより噴霧することによりA剤にpH
調整成分を均一に含浸させる方法が挙げられる。
The pH adjusting component in the present invention is preferably added after the A agent component is granulated and dried. It is preferable that the pH-adjusting component is added uniformly into the granulated A-agent particles, and specific means for uniformly adding the pH-adjusting component to the A-agent include, for example, adjusting the pH while stirring the A-agent. By spraying the ingredients, the pH is adjusted to the A agent.
One example is a method of uniformly impregnating the adjusting component.

【0017】本発明のB剤は、重曹のみを含むものでも
重曹とA剤成分の一部の混合物でも良い。B剤にブドウ
糖を配合する場合は、細菌が増殖しやすいので注意が必
要である。
The B agent of the present invention may contain only sodium bicarbonate, or may be a mixture of baking soda and a portion of the A agent components. When adding glucose to Agent B, care must be taken as bacteria are likely to proliferate.

【0018】本発明の重曹透析用剤を用いて、透析液を
作製するには、A剤およびB剤を必要な濃度になるよう
溶解して混合すれば良い。特にpHの調整を行わなくと
も、所定のpHの透析液が得られ、かつカルシウムまた
はマグネシウム成分の沈澱が生成しない。
To prepare a dialysis solution using the sodium bicarbonate dialysis agent of the present invention, agents A and B may be dissolved and mixed to a required concentration. A dialysate having a predetermined pH can be obtained without particularly adjusting the pH, and no precipitate of calcium or magnesium components is generated.

【0019】[0019]

【実施例】(実施例1)それぞれ平均粒径50μm程度
に粉砕された日本薬局方の塩化ナトリウム、塩化カリウ
ム、塩化カルシウム2水和物、塩化マグネシウム6水和
物、酢酸ナトリウム無水物及びブドウ糖を下記の比率で
混合し、さらに乾燥基準で1.5 重量%の水を添加し
て混合した。 NaCl              74.7110
 重量%KCl                 1
.7943 重量%CaCl2・2H2 O     
2.2839 重量%MgCl2・6H2 O    
 1.2408 重量%CH3 COONa     
  7.9296 重量%ブドウ糖         
     12.0404 重量%
[Example] (Example 1) Sodium chloride, potassium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, sodium acetate anhydrous and glucose of the Japanese Pharmacopoeia were each ground to an average particle size of about 50 μm. The following ratios were mixed, and 1.5% by weight of water on a dry basis was added and mixed. NaCl 74.7110
Weight% KCl 1
.. 7943 wt%CaCl2.2H2O
2.2839 wt%MgCl2.6H2O
1.2408 wt% CH3 COONa
7.9296 weight% glucose
12.0404% by weight

【0020】この混
合物をスクリーン径0.5mm の押し出し造粒機を用
いて造粒し、直径0.5mm 、長さ1 〜10mmの
円柱状の粒子を100kg 得た。次に、事前に相対湿
度を50%まで脱湿した空気を吹き込みつつ温度50℃
に調整された回分式箱型乾燥機に前記粒子を入れ3時間
乾燥した。 乾燥後の顆粒を撹拌しつつスプレーにより氷酢酸を1.
6 重量%噴霧し本発明のA剤を得た。このA剤は顆粒
状であり、水銀圧入式ポロシメーターにより測定した細
孔容積は、0.08cc/gであった。
This mixture was granulated using an extrusion granulator with a screen diameter of 0.5 mm to obtain 100 kg of cylindrical particles with a diameter of 0.5 mm and a length of 1 to 10 mm. Next, the temperature was raised to 50°C while blowing in air that had been dehumidified to a relative humidity of 50% in advance.
The particles were placed in a batch type box dryer adjusted to dry for 3 hours. While stirring the dried granules, spray glacial acetic acid 1.
6% by weight was sprayed to obtain agent A of the present invention. This A agent was in the form of granules, and the pore volume measured by a mercury intrusion porosimeter was 0.08 cc/g.

【0021】重曹97.6重量%および塩化ナトリウム
2.4 重量%を混合して、A剤と同様な方法で造粒し
、B剤を得た。
[0021] 97.6% by weight of sodium bicarbonate and 2.4% by weight of sodium chloride were mixed and granulated in the same manner as Part A to obtain Part B.

【0022】A剤2654g を純水に溶解し9リット
ルとした溶液をA液とし、B剤678gを純水に溶解し
11.34 リットルとした溶液をB液とし、B液の1
.26リットルに純水を加えて34リットルとした溶液
にA液1リットルを混合した溶液が人工透析に使用時の
濃度の溶液である。希釈混合中に沈殿はまったく発生し
なかった。この希釈混合溶液のpHは7.3 であった
。またA剤中の氷酢酸の含量の定量はフェノールフタレ
インを指示薬とした酸アルカリ滴定にて可能である。
A solution of 2,654 g of agent A dissolved in pure water to make 9 liters is called solution A, and a solution of 678 g of agent B dissolved in pure water to make 11.34 liters is called solution B.
.. A solution obtained by mixing 1 liter of solution A with 26 liters of solution made by adding pure water to make 34 liters is a solution with a concentration used for artificial dialysis. No precipitation occurred during dilution mixing. The pH of this diluted mixed solution was 7.3. Furthermore, the content of glacial acetic acid in Part A can be determined by acid-alkali titration using phenolphthalein as an indicator.

【0023】(実施例2〜5)それぞれ実施例1と全く
同様な操作により粉砕、混合、及び造粒したA剤を温度
50℃に調整された回分式箱型乾燥機に入れ乾燥後、更
に氷酢酸を各々0.9 、1.1 、1.7 及び2.
1 重量%加えて、これを実施例2、3、4及び5とし
た。実施例1と同様にして希釈混合して得た溶液のpH
および細孔容積を表1に示す。希釈混合中に沈殿はまっ
たく発生しなかった。
(Examples 2 to 5) Agent A, which was pulverized, mixed, and granulated in the same manner as in Example 1, was placed in a batch-type box dryer adjusted to a temperature of 50°C, and then dried. Glacial acetic acid at 0.9, 1.1, 1.7 and 2.
Examples 2, 3, 4 and 5 were obtained by adding 1% by weight. pH of the solution obtained by diluting and mixing in the same manner as in Example 1
and pore volume are shown in Table 1. No precipitation occurred during dilution mixing.

【0024】(実施例6)実施例1と全く同様な操作に
より粉砕、混合、及び造粒したA剤を温度50℃に調整
された回分式箱型乾燥機に入れ乾燥後、更に乳酸を2.
4 重量%加えて、これを実施例6とした。実施例1と
同様にして希釈混合して得た溶液のpHおよび細孔容積
を表1に示す。希釈混合中に沈殿はまったく発生しなか
った。
(Example 6) Part A, which was pulverized, mixed, and granulated in exactly the same manner as in Example 1, was placed in a batch-type box dryer adjusted to a temperature of 50°C, and after drying, lactic acid was added to ..
4% by weight was added, and this was designated as Example 6. Table 1 shows the pH and pore volume of the solution obtained by diluting and mixing in the same manner as in Example 1. No precipitation occurred during dilution mixing.

【0025】[0025]

【表1】[Table 1]

【0026】[0026]

【発明の効果】本発明の透析用剤は水に溶解して均質な
水溶液となり、使用時にpH調整成分を別途添加する必
要が無く安全かつ簡単に透析液を得ることができる。A
剤は造粒されているため流動性に優れているので、取扱
いが容易である。また、本透析用剤は、固形化されてお
り従来の溶液型人工透析剤に比して体積を小さくできる
。本発明の透析用剤は、貯留時に粉化したりあるいは難
溶性の化合物が生成したりせず保存あるいは輸送に有利
である。
Effects of the Invention The dialysis agent of the present invention dissolves in water to form a homogeneous aqueous solution, and a dialysate can be obtained safely and easily without the need to separately add a pH adjusting component during use. A
Since the agent is granulated, it has excellent fluidity and is easy to handle. Furthermore, the present dialysis agent is solidified and can be made smaller in volume than conventional solution-type artificial dialysis agents. The dialysis agent of the present invention is advantageous in storage and transportation since it does not turn into powder or generate poorly soluble compounds during storage.

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】重曹透析用剤に含まれる電解質成分のうち
重曹以外の成分から選ばれた1種以上からなる群(A剤
)と、重曹を主成分とする群(B剤)とに分け、使用時
にA剤とB剤を混合して用いる重曹透析用剤において、
A剤が造粒された粒子であり、かつ、粒子内にpH調制
剤として酸を含むことを特徴とする重曹透析用剤。
Claim 1: A group consisting of one or more electrolyte components other than sodium bicarbonate among the electrolyte components contained in the sodium bicarbonate dialysis agent (agent A), and a group containing baking soda as the main component (agent B). , in a sodium bicarbonate dialysis agent that uses a mixture of agent A and agent B during use,
A sodium bicarbonate dialysis agent characterized in that agent A is granulated particles and contains an acid as a pH regulator in the particles.
【請求項2】酸が、酢酸または乳酸、あるいは酢酸と乳
酸との混合物である請求項1の重曹透析用剤。
2. The sodium bicarbonate dialysis agent according to claim 1, wherein the acid is acetic acid, lactic acid, or a mixture of acetic acid and lactic acid.
【請求項3】A剤の細孔容積が0.03〜0.2cc/
g である請求項1または請求項2の重曹透析用剤。
Claim 3: The pore volume of agent A is 0.03 to 0.2 cc/
The sodium bicarbonate dialysis agent according to claim 1 or 2, which is
JP3036525A 1991-02-07 1991-02-07 Dialyzing agent for sodium bicarbonate Pending JPH04257522A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3036525A JPH04257522A (en) 1991-02-07 1991-02-07 Dialyzing agent for sodium bicarbonate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3036525A JPH04257522A (en) 1991-02-07 1991-02-07 Dialyzing agent for sodium bicarbonate

Publications (1)

Publication Number Publication Date
JPH04257522A true JPH04257522A (en) 1992-09-11

Family

ID=12472218

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3036525A Pending JPH04257522A (en) 1991-02-07 1991-02-07 Dialyzing agent for sodium bicarbonate

Country Status (1)

Country Link
JP (1) JPH04257522A (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06178802A (en) * 1992-12-14 1994-06-28 Tomita Seiyaku Kk Production of agent for artificial kidney perfusion for bicarbonate dialysis and the agent
JPH0892071A (en) * 1994-09-27 1996-04-09 Morishita Roussel Kk Bicarbonate dialyzing agent
EP1120110A1 (en) * 2000-01-11 2001-08-01 Vasa di Sala Vittorio & C. S.n.c. A composition for the preparation of dialytic solutions, a method for the production thereof, and a respective package
KR100398299B1 (en) * 1995-08-02 2003-12-31 도미따 세이야꾸 가부시끼가이샤 Solid dialysis solvent and method for manufacturing the same
US6673376B1 (en) * 1998-11-04 2004-01-06 Fresenius Medical Care Deutschland Gmbh Method of preparing a solution, in particular a dialysis or infusion solution
US9616161B2 (en) 2011-06-20 2017-04-11 Gambro Lundia Ab Dialysis precursor composition
US9687507B2 (en) 2011-12-21 2017-06-27 Gambro Lundia Ab Dialysis precursor composition
US9724298B2 (en) 2012-03-08 2017-08-08 Gambro Lundia Ab Method to form a dialysis composition comprising citrate, calcium and magnesium
US9821102B2 (en) 2011-06-20 2017-11-21 Gambro Lundia Ab Dialysis precursor composition
US9833470B2 (en) 2011-12-21 2017-12-05 Gambro Lundia Ab Dialysis precursor composition
US9925155B2 (en) 2012-12-18 2018-03-27 Gambro Lundia Ab Dialysis composition
US10993961B2 (en) 2010-06-23 2021-05-04 Gambro Lundia Ab Dialysis precursor composition
US11253543B2 (en) 2010-06-23 2022-02-22 Gambro Lundia Ab Dialysis precursor composition product

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06178802A (en) * 1992-12-14 1994-06-28 Tomita Seiyaku Kk Production of agent for artificial kidney perfusion for bicarbonate dialysis and the agent
JPH0892071A (en) * 1994-09-27 1996-04-09 Morishita Roussel Kk Bicarbonate dialyzing agent
KR100398299B1 (en) * 1995-08-02 2003-12-31 도미따 세이야꾸 가부시끼가이샤 Solid dialysis solvent and method for manufacturing the same
US6673376B1 (en) * 1998-11-04 2004-01-06 Fresenius Medical Care Deutschland Gmbh Method of preparing a solution, in particular a dialysis or infusion solution
EP1120110A1 (en) * 2000-01-11 2001-08-01 Vasa di Sala Vittorio & C. S.n.c. A composition for the preparation of dialytic solutions, a method for the production thereof, and a respective package
US10993961B2 (en) 2010-06-23 2021-05-04 Gambro Lundia Ab Dialysis precursor composition
US11253543B2 (en) 2010-06-23 2022-02-22 Gambro Lundia Ab Dialysis precursor composition product
US9655922B1 (en) 2011-06-20 2017-05-23 Gambro Lundia Ab Dialysis precursor composition
US9821102B2 (en) 2011-06-20 2017-11-21 Gambro Lundia Ab Dialysis precursor composition
US9616161B2 (en) 2011-06-20 2017-04-11 Gambro Lundia Ab Dialysis precursor composition
US9833470B2 (en) 2011-12-21 2017-12-05 Gambro Lundia Ab Dialysis precursor composition
US10172881B2 (en) 2011-12-21 2019-01-08 Gambro Lundia Ab Dialysis precursor composition
US9687507B2 (en) 2011-12-21 2017-06-27 Gambro Lundia Ab Dialysis precursor composition
US9724298B2 (en) 2012-03-08 2017-08-08 Gambro Lundia Ab Method to form a dialysis composition comprising citrate, calcium and magnesium
US9925155B2 (en) 2012-12-18 2018-03-27 Gambro Lundia Ab Dialysis composition

Similar Documents

Publication Publication Date Title
EP0417478B2 (en) Sodium bicarbonate containing mixture for producing a dialysis solution
US6923987B2 (en) Solid preparation for dialysis and process for producing the same
EP2151247B1 (en) Solid dialysis preparation
US20070190161A1 (en) Solid formulation for dialysis and process for producing the same
JPH04257522A (en) Dialyzing agent for sodium bicarbonate
JP6366214B1 (en) Agent A for hemodialysis
JP3433979B2 (en) Dialysis agent and method for producing the same
EP1192960B1 (en) Solid preparation for dialysis and process for producing the same
JP3530235B2 (en) Hemodialysis agent
JP2809971B2 (en) Hemodialysis preparation
JP3415291B2 (en) Bicarbonate dialysis agent
JP2986810B2 (en) Dialysis agent and method for producing the same
JPH11114054A (en) Solid dialysis agent
JP2001518482A (en) Phosphonium salt composition
JPH10259133A (en) Particulate agent for dialysis and its production
JP3076051B2 (en) Baking soda dialysis agent
JP6593047B2 (en) Solid preparation for dialysate
JP3714050B2 (en) Solid baking soda dialysis agent and method for producing the same
JPH06105906A (en) Agent for dialysis
JP4328851B2 (en) Bicarbonate solid dialysate
JPH0570357A (en) Granule for hemodialysis
JP6312957B1 (en) Agent A for hemodialysis
JPH02311419A (en) Pharmaceutical for hemodialysis and its production
JP4483806B2 (en) Preparation for solid dialysis and method for producing the same
JP2017052741A (en) Solid preparation for dialysis fluid, and method of producing the same